The UK's life sciences industry benefits from a long-term vision and partnership with governments, and it's supported by a world class talent base.
In 2022, the UK life science sector secured a total of £3.3 billion in equity financing, an increase of 500% since 2012. UK scientists continue to be at the forefront of science and discovery, responsible for discovering around 25 per cent of the world's top 100 prescription medicines and leading the way in COVID-19 vaccines. Our plans for future growth are outlined in the Life Sciences Visionopens www.gov.uk in a new tab.
Companies investing in the UK benefit from access to world-class universities and life sciences infrastructure including lab space, science parks and manufacturing facilities, as well as incubators and accelerators in which to start up and scale up. A national health research network supports streamlined trials operations, and innovation support is available from the regulator, health technology assessment bodies, and the NHS.
Specialised clusters offer opportunities in high growth subsectors such as precision medicine, cell and gene therapies, vaccine manufacturing, data science and more. Innovators can connect to R&D opportunities across the UK, and benefit from both national and regional networks that can help to facilitate partnerships.
A few of the notable UK assets include:
To find out more about the life sciences sector in the UK, visit the Healthcare and Life Sciences sector page on the Department for Business and Trade's Investment Atlas.